SMN2 and proximal spinal muscular atrophy: Most recently, risdiplam, an oral, well‐tolerated small molecule SMN2 splicing modifier, was approved for the treatment of SMA patients, based on positive results from randomized placebo‐controlled clinical trials in patients with type 1, type 2, or non‐ambulant type 3 SMA, up to an age of 25 years [7, 8, 9].